A Greater Cincinnati biopharma startup that’s developing new interventions for acute and chronic lung diseases this week received another key U.S. Food and Drug Administration approval.
Click here to read the complete story.
Story excerpt provided by Cincinnati Business Courier.
Written by Liz Engel.
Originally published April 12, 2021.